Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
1 hedge funds and large institutions have $0 invested in Impax Laboratories, Inc. in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 185 closing their positions.
99% less funds holding
Funds holding: 188 → 1 (-187)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $1.42B → $0 (-$1.42B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 185
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$191M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$145M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$93.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$81.3M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
-$78.6M |
IPXL Hedge Fund Activity: Q2 2018 in Review
1 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q2 2018, worth a combined $0 — down 100% from $1.42B a quarter earlier.
Sellers outnumbered buyers: 185 funds closed out of IPXL and 0 opened new positions — a net loss of 185 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $191M sold.
- 1 institutional investor held Impax Laboratories, Inc. (IPXL) as of Q2 2018, down from 188 in Q1 2018.
- Funds reported $0 of Impax Laboratories, Inc. stock for Q2 2018, down 100% quarter-over-quarter.
- 0 funds opened new Impax Laboratories, Inc. positions in Q2 2018 and 185 closed out, a net change of -185 holders.
- The largest Impax Laboratories, Inc. seller in Q2 2018 was BlackRock, an estimated $191M sold.
Based on aggregated 13F filings for Q2 2018.